image
Healthcare - Medical - Devices - NASDAQ - US
$ 138.0
4.45 %
$ 4.67 B
Market Cap
95.49
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TMDX stock under the worst case scenario is HIDDEN Compared to the current market price of 138 USD, TransMedics Group, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TMDX stock under the base case scenario is HIDDEN Compared to the current market price of 138 USD, TransMedics Group, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TMDX stock under the best case scenario is HIDDEN Compared to the current market price of 138 USD, TransMedics Group, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TMDX

image
$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
442 M REVENUE
82.74%
37.5 M OPERATING INCOME
230.53%
35.5 M NET INCOME
241.70%
48.8 M OPERATING CASH FLOW
474.60%
-129 M INVESTING CASH FLOW
33.33%
22.9 M FINANCING CASH FLOW
-94.29%
144 M REVENUE
18.02%
27.4 M OPERATING INCOME
217.48%
25.7 M NET INCOME
274.54%
-2.86 M OPERATING CASH FLOW
-14.52%
-27 M INVESTING CASH FLOW
-98.72%
3.03 M FINANCING CASH FLOW
155.31%
Balance Sheet TransMedics Group, Inc.
image
Current Assets 497 M
Cash & Short-Term Investments 337 M
Receivables 97.7 M
Other Current Assets 62.8 M
Non-Current Assets 307 M
Long-Term Investments 0
PP&E 292 M
Other Non-Current Assets 14.4 M
41.87 %12.15 %7.82 %36.37 %Total Assets$804.1m
Current Liabilities 59.9 M
Accounts Payable 10.3 M
Short-Term Debt 2.73 M
Other Current Liabilities 46.9 M
Non-Current Liabilities 516 M
Long-Term Debt 516 M
Other Non-Current Liabilities 0
8.15 %89.59 %Total Liabilities$575.5m
EFFICIENCY
Earnings Waterfall TransMedics Group, Inc.
image
Revenue 442 M
Cost Of Revenue 179 M
Gross Profit 262 M
Operating Expenses 225 M
Operating Income 37.5 M
Other Expenses 2.03 M
Net Income 35.5 M
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00442m(179m)262m(225m)37m(2m)35mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.36% GROSS MARGIN
59.36%
8.49% OPERATING MARGIN
8.49%
8.03% NET MARGIN
8.03%
15.51% ROE
15.51%
4.41% ROA
4.41%
4.98% ROIC
4.98%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TransMedics Group, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 35.5 M
Depreciation & Amortization 19.8 M
Capital Expenditures -130 M
Stock-Based Compensation 33.2 M
Change in Working Capital -45 M
Others 37.6 M
Free Cash Flow -80.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TransMedics Group, Inc.
image
Wall Street analysts predict an average 1-year price target for TMDX of $152 , with forecasts ranging from a low of $90 to a high of $208 .
TMDX Lowest Price Target Wall Street Target
90 USD -34.78%
TMDX Average Price Target Wall Street Target
152 USD 10.09%
TMDX Highest Price Target Wall Street Target
208 USD 50.72%
Price
Max Price Target
Min Price Target
Average Price Target
220220200200180180160160140140120120100100808060604040Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership TransMedics Group, Inc.
image
Sold
0-3 MONTHS
1.42 M USD 2
3-6 MONTHS
271 K USD 1
6-9 MONTHS
3.78 M USD 3
9-12 MONTHS
18.5 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 2 weeks ago
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy? TransMedics Group, Inc. (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross. zacks.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 3 weeks ago
Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm NEW YORK , May 27, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at TransMedics caused the company to misrepresent or fail to disclose (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, statements about TransMedics' business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. prnewswire.com - 3 weeks ago
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANDOVER, Mass. , May 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 21, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 9,940 shares of its common stock and an aggregate of 6,670 restricted stock units to 15 employees, each as a material inducement for each employee's entry into employment with TransMedics. prnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 3 weeks ago
Reasons to Retain TransMedics Stock in Your Portfolio for Now TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program. zacks.com - 4 weeks ago
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 4 weeks ago
TransMedics: Extremely Undervalued And Extremely Innovative TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat and growth trajectory remain compelling. seekingalpha.com - 1 month ago
TransMedics to Present at Upcoming June Investor Conferences ANDOVER, Mass. , May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. prnewswire.com - 1 month ago
8. Profile Summary

TransMedics Group, Inc. TMDX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 4.67 B
Dividend Yield 0.00%
Description TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Contact 200 Minuteman Road, Andover, MA, 01810 https://www.transmedics.com
IPO Date May 2, 2019
Employees 728
Officers Mr. Anil Ranganath Senior Vice President, General Counsel & Corporate Secretary Ms. Miriam C. Provost Ph.D. Vice President of Global Regulatory Affairs Mr. Gerardo Hernandez Chief Financial Officer & Treasurer Dr. Waleed H. Hassanein M.D. Founder, President, Chief Executive Officer & Director Mr. Nicholas Corcoran Senior Vice President of Supply Chain & Operations Dr. Tamer I. Khayal M.D. Chief Commercial Officer